Nabriva

NBRV NASDAQ
2.120
+0.050
+2.42%
交易中 15:12 06/18 EDT
开盘
2.070
昨收
2.070
最高
2.140
最低
2.070
成交量
34.82万
成交均量(3M)
125.24万
52周最高
4.580
52周最低
1.120
换手率
0.48%
市值
1.54亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Nabriva NBRV股票价格,Nabriva股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.
展开 >

最近浏览

名称
价格
涨跌幅